Direct trial. Diverticulitis recurrences or continuing symptoms: Operative versus conservative Treatment. A Multicenter randomised clinical trial by Wall, B.J.M. (Bryan) van de et al.
STUDY PROTOCOL Open Access
DIRECT trial. Diverticulitis recurrences or
continuing symptoms: Operative versus
conservative Treatment. A MULTICENTER
RANDOMISED CLINICAL TRIAL
Bryan JM van de Wall1, Werner A Draaisma1, Esther CJ Consten1*, Yolanda van der Graaf2, Marten H Otten3,
G Ardine de Wit2, Henk F van Stel2, Michael F Gerhards4, Marinus J Wiezer5, Huib A Cense6, Hein BAC Stockmann7
, Jeroen WA Leijtens8, David DE Zimmerman9, Eric Belgers10, Bart A van Wagensveld11, Eric DJA Sonneveld12,
Hubert A Prins13, Peter PLO Coene14, Tom M Karsten15, Joost M Klaase16, Markwin G Statius Muller17,
Rogier MPH Crolla18, Ivo AMJ Broeders1*, the Dutch Diverticular Disease (3D) Collaborative Study Group
Abstract
Background: Persisting abdominal complaints are common after an episode of diverticulitis treated conservatively.
Furthermore, some patients develop frequent recurrences. These two groups of patients suffer greatly from their
disease, as shown by impaired health related quality of life and increased costs due to multiple specialist
consultations, pain medication and productivity losses.
Both conservative and operative management of patients with persisting abdominal complaints after an episode of
diverticulitis and/or frequently recurring diverticulitis are applied. However, direct comparison by a randomised
controlled trial is necessary to determine which is superior in relieving symptoms, optimising health related quality
of life, minimising costs and preventing diverticulitis recurrences against acceptable morbidity and mortality asso-
ciated with surgery or the occurrence of a complicated recurrence after conservative management.
We, therefore, constructed a randomised clinical trial comparing these two treatment strategies.
Methods/design: The DIRECT trial is a multicenter randomised clinical trial. Patients (18-75 years) presenting
themselves with persisting abdominal complaints after an episode of diverticulitis and/or three or more recurrences
within 2 years will be included and randomised. Patients randomised for conservative treatment are treated according
to the current daily practice (antibiotics, analgetics and/or expectant management). Patients randomised for elective
resection will undergo an elective resection of the affected colon segment. Preferably, a laparoscopic approach is used.
The primary outcome is health related quality of life measured by the Gastro-intestinal Quality of Life Index, Short-
Form 36, EQ-5D and a visual analogue scale for pain quantification. Secondary endpoints are morbidity, mortality
and total costs. The total follow-up will be three years.
Discussion: Considering the high incidence and the multicenter design of this study, it may be assumed that the
number of patients needed for this study (n = 214), may be gathered within one and a half year.
Depending on the expertise and available equipment, we prefer to perform a laparoscopic resection on patients
randomised for elective surgery. Should this be impossible, an open technique may be used as this also reflects
the current situation.
Trial Registration: (Trial register number: NTR1478)
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Background
The recurrence rate of patients treated conservatively for
an episode of diverticulitis is approximately 25% [1]. Elec-
tive resection has traditionally been advised after a sec-
ond episode of diverticulitis. It has been thought that
patients with a diverticulitis recurrence are at greater risk
of developing complications, have higher mortality rates
and are less likely to respond to medical treatment [2].
However, recent studies have demonstrated that the
number of attacks of diverticulitis is not necessarily a
prevailing factor in defining the suitability of surgery.
Most patients who present with complicated diverticulitis
do so at the time of their first attack. Furthermore, only a
fraction (5-7%) develops complicated diverticulitis during
subsequent attacks [3,4]. This and the fact that operation
itself carries significant morbidity and mortality, has lead
to reluctance in gastroenterologists and surgeons towards
elective resection after a recurrence of the disease.
However, elective resection may be an appropriate
solution for a more selective group of patients who suf-
fer greatly from their disease. Many studies have consis-
tently shown that 40-80% remain symptomatic after
conservative treatment, leading to impaired health-
related quality of life (HRQoL) and increased costs due
to multiple specialist consultations, pain medication and
productivity losses [1]. Logically, this is also the case for
patients who continue developing diverticulitis recur-
rences on a frequent basis. Also, these patients often
remain symptomatic in between the recurrences.
In addition of possibly preventing further recurrences
and complications of diverticulitis, elective resection has
frequently been demonstrated to relieve persisting symp-
toms after an episode of diverticulitis [5,6]. Therefore,
many physicians and patients seem to abandon expec-
tant/conservative management and subsequently choose
elective resection.
Both conservative and operative management of
patients with persisting abdominal complaints after an
episode of diverticulitis and/or frequently recurring
diverticulitis are applied. However, direct comparison by
a randomised controlled trial is necessary to determine
which is superior in relieving symptoms, optimising
HRQoL, minimising costs and preventing diverticulitis
recurrences against acceptable morbidity and mortality
associated with surgery or the occurrence of a compli-
cated recurrence after conservative management.
Methods
Study objective
The DIRECT trial is a multicenter randomised clinical
trial. The objective is to compare conservative manage-
ment to elective resection of the diseased colon segment
in patients with persisting abdominal complaints after
an episode of diverticulitis and/or frequently recurring
diverticulitis. We hypothesize that elective resection is
superior in relieving abdominal complaints, preventing
further hospitalisation and specialist consultation and
minimising direct and indirect hospital costs against
acceptable morbidity and mortality compared to conser-
vative management.
Study population
Inclusion criteria
- Age 18-75 years.
- Patients presenting with either persisting abdom-
inal complaints and/or frequently recurring diverti-
culitis after a well documented (CT-scan or
ultrasonography) episode of diverticulitis.
Persisting abdominal complaints may include
patients with:
- continuing lower left abdominal pain AND/
OR persistent change in bowel habits AND/
OR persistent blood loss.
- Symptoms must exist longer than 3 months
after a previous episode of diverticulitis
Frequently recurring diverticulitis is defined as:
- Three or more diverticulitis recurrences
within 2 years.
- A minimal interval of 3 months between the
recurrences is mandatory.
- Persisting abdominal complaints and/or frequently
recurring diverticulitis must be accompanied by
inflammatory changes (CT-scan or ultrasonography)
in the bowel wall: Bowel-wall thickening with or
without abscess.
- ASA I-III.
Exclusion criteria
- Patients with elective or emergency surgery for
acute diverticulitis in the past.
- Patients with an absolute operation indication (per-
foration with purulent/fecal peritonitis, symptomatic
bowel stenosis or fistula).
- Patients with colorectal malignancies.
- Patients in ASA class III who are at high risk for
per- and postoperative complications due to severe
co-morbidity as regarded by the surgeon and/or the
patients specialists
- Patients with a psychiatric disease or other condi-
tions making them incapable of filling out the ques-
tionnaires or completing the objective follow up
tests.
Study endpoints
Primary endpoint
Health-related quality of life (HRQoL) objectified pri-
marily by the Gastro-intestinal Quality of life Index
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(GIQLI) and secondarily by EuroQol-5D (EQ-5D),
Short-form 36 (SF-36) and Visual Analogue Score
(VAS) for pain. Patients are also asked to point out on a
7 point Likert scale whether their health and complaints
have improved or deteriorated in comparison to the pre-
vious assessment.
Secondary endpoints
1. Mortality defined as:
○ Elective surgery: 30-days mortality.
○ Both groups: Mortality associated with the
development of complications related to diverti-
culitis during follow-up.
2. Morbidity defined as:
○ Diverticulitis recurrence
○ Perforation (with purulent/fecal peritonitis)
○ Fistula
○ Symptomatic stenosis
○ Abscess
○ Stoma formation
○ Emergency surgery or re-operation
○ Peri- and postoperative complications
3. Direct health care costs. In-hospital resource use
will be recorded. During follow-up medication use,
general practitioner and specialist visits will be mea-
sured at baseline and regular intervals with custo-
mized questionnaires.
4. Indirect non-health care costs, using a standar-
dised ShortForm-health and labour questionnaire
(SF-H&L) at baseline and regular intervals during
follow-up.
All questionnaires are asked to be filled in at baseline
and 3, 6, 9, 12, 24 and 36 months after treatment
Sample size
The sample size calculation is based on the minimum
important difference* (MID) of the GIQLI score. The
MID can be estimated by taking half a standard devia-
tion of a quality of life instrument [7,8].
Based on the studies of Forgione et al and Zdichavsk
et al the MID of the GIQLI score is estimated at 10
points [5,6]. They also demonstrated that patients
improve with 10 points on the GIQLI score one month
to one year after elective resection (111 ± 20.4 and
105.8 ± 15.5) for diverticulitis compared to preopera-
tively (100 ± 22.1 and 95.3 ± 21.4). In conclusion, a dif-
ference of 10 points corresponds with the MID and the
expected improvement after elective resection.
To demonstrate this difference using an independent
t-test (alpha = 0.05, delta = 10, sigma = 21, power =
0.9) approximately N = 97 patients per group are
needed for this study. Therefore a total study population
of 194 patients is required to attain statistical
significance.
To compensate for a potential loss to follow-up of
10%, 214 patients will be included.
* Minimum important difference (MID): The smallest
difference in score in the domain of interest which
patients perceive as beneficial and which would man-
date, in the absence of troublesome side effects and
excessive cost, a change in the patient’s (health care)
management.
Treatment of Subjects
Conservative treatment
Patients randomised for conservative treatment are trea-
ted according to the current daily practice. In other
words, conservative treatment is determined by the pre-
ferences of the treating physician. Conservative treat-
ment may consist of expectant management, antibiotics
and/or analgetics. Should there be radiologic evidence
for the presence of pericolic abscesses, percutaneous
drainage may be performed depending on the size and
opinion of the local radiologist regarding accessibility.
Elective surgery
Patients randomised for elective surgery will undergo an
elective colonic resection within approximately 6 weeks.
In the interval between randomisation and elective sur-
gery, patients are treated conservatively (see above).
Intentionally, a laparoscopic approach is used. The
extent to which the colon is resected in the proximal
direction should cover the entire macroscopically
involved colon. In other words, the proximal resection
line should be where no diverticula exist or at the level
where a considerable decline in number of diverticula is
noted. Distally, the margin of resection should be where
the taenia coli splay out onto the upper rectum. After
resection a primary anastomosis will be performed
between the distal colon and rectum.
Randomisation (figure 1)
All patients presenting themselves with persisting
abdominal complaints after an episode of diverticulitis
and/or a third (or more) diverticulitis recurrence,
require to have had a recent radiological examination of
the abdomen. Preferably a CT-scan is used. However,
ultrasonography may also be used on the condition that
bowel wall thickening and abscess size can be assessed
accurately. Colonoscopy may be performed on indica-
tion to exclude malignancy.
If all inclusion criteria are met, patients are informed
about the study protocol by their treating physician.
They are given a 3 day reflective period, together with
the information package. After the reflective period, the
patient is contacted and asked for participation. If the
patient decides to take part in the trial, he/she is invited
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to the local hospital to sign the informed consent. After
receiving this consent form, randomisation will be per-
formed centrally by the study coordinator using block
randomisation (block size 6) stratified for center and
inclusion criteria (persisting abdominal symptoms or
frequent recurrences).
Both patients in the conservative and elective resec-
tion group will be treated conservatively in case of
events during follow-up unless there is an absolute indi-
cation for surgery according to the treating physician
(e.g. fistula, symptomatic stenosis, perforation with
purulent/fecal peritonitis). In addition, in case of persist-
ing abdominal symptoms during follow-up (in the con-
servative group) which are regarded as unbearable by
both patient and treating physician, the treating physi-
cian may consult an independent event adjudication
committee. The independent committee will advise the
treating physician whether or not to abandon conserva-
tive management and proceed to elective resection. The
final decision is made by the treating physician.
Data collection
Data are collected by a local research fellow and/or
treating physician at baseline, postoperatively (if rando-
mised for elective resection), during outpatient visits
and in case of adverse events leading to hospitalisation
during follow-up. Case record forms on paper are used
and faxed to the data manager.
Patients are asked to fill out HRQoL questionnaires at
baseline. These questionnaires, as well as resource use
and productivity losses questionnaires, are also sent to
the patients at 3,6,9,12,24 and 36 months follow-up.
Data integrity will be checked when receiving the
questionnaire. Any missing items will be collected by
contacting the patient by telephone. Reminders (includ-
ing a new copy of the questionnaire) will be send after
two weeks.
Statistical analysis
The statistical package SPSS will be used for analysis.
All analyses will be performed according the intention
to treat principle.
Baseline characteristics will be described as means and
standard deviations. Large differences between treatment
groups will be analysed with an independent Student’s
T-test to verify significance (p-value < 0.05). Significant
differences will be adjusted for in the final analysis.
The primary outcome will be analysed using mixed
linear models with random effects. The covariates of the
random part of the model will be determined using
restricted maximum likelihood estimation (REML) and
selected on the basis of Akaike Information Criterium
(AIC). For the fixed part, models will be constructed
containing either the treatment effect adjusted for time
with or without an interaction term of these compo-
nents. The models will be compared using AIC. Missing
data will be imputed using multiple imputation.
The estimates of the final model will be used to test
whether or not there is a clinical difference between the
treatment groups. As described before, the MID is 10
points on the GIQLI scale. Therefore, the MID will be
subtracted from the estimated difference between treat-
ment groups and tested with Wald’s test against a
p-value of 0.10.
Additionally, the 7 point scale reflecting self-reported
improvement of complaints over time, will be used to
confirm whether the assumption of MID being the
equivalent of half a standard deviation, holds.
Categorical outcome measures will tested using the
chi-square test (p-value < 0.05) and described as percen-
tages and counts.
Economic evaluation
The cost analysis will be performed form a societal per-
spective including total direct health care costs and
indirect non-health care costs (productivity losses).
Direct health care costs include costs related to hospi-
talization, imaging, blood tests, colonoscopy, medication,
interventions, operations, consultations, complications
and primary health care contacts. On an individual
Figure 1 Flowchart DIRECT trial
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patient basis, resource use will be recorded. Subse-
quently, by multiplying resource use with unit price,
actual costs per patient will be calculated. Unit costs
will be derived from the Dutch costing manual or deter-
mined in co-operation with hospital administration.
Health care consumption including general practi-
tioner or specialist visits and medication use will be
assessed using customised questionnaires and case
report forms.
Indirect non-health care costs include sick leave from
paid work, own expenses of patients and time and travel
costs. Sick leave from paid work will be assessed using the
ShortForm-Health and Labour questionnaire. The remain-
ing indirect non-health costs will be assessed using custo-
mised questionnaires to be completed by participants.
The cost-effectiveness will be expressed as incremental
costs per quality-adjusted life year (QALY) gained.
QALY gains over time will be assessed using the EQ-5D
classification system as completed by patients, in combi-
nation with pre-defined value sets for all possible health
states. The time perspective of the analysis will be
3 years.
Patient safety
After inclusion and completion of half a year follow-up
of 25% of patients and after one year follow-up of 50%
of patients in both groups, interim analysis will take
place. A safety-monitoring committee consisting of
independent physicians will review the results and
advice the steering committee of the trial. The steering
committee will decide on the continuation of the trial.
In addition all severe adverse events will be reported
to the central Medical Ethics Committee and the inde-
pendent safety-committee. The safety committee will
discuss the events and will advice the trial steering-
committee on the safety of the trial.
Ethics
The study is conducted in accordance with the principles
of the Declaration of Helsinki and “good clinical practice”
guidelines. The protocol has been approved by the the
medical ethical committee “Verenigde Commissies
Mensgebonden Onderzoek”, located at the St. Antonius
Hospital, Nieuwegein, the Netherlands. Prior to randomi-
sation, informed consent will be obtained form all
patients.
Discussion
Acute diverticulitis is diagnosed about 300 times alone
at the department of surgery at the Meander Medical
Center Amersfoort per year. A significant part consists
of patients with persisting abdominal symptoms and fre-
quent recurrences. Considering the high incidence and
the multicenter design of this study, it may be assumed
that the number of patients needed for this study (n =
214), may be gathered within one and a half year.
Depending on the expertise and available equipment, a
laparoscopic approach is preferred for patients rando-
mised for elective sigmoidresection. Preliminary results
of the SIGMA trial have shown that elective laparo-
scopic sigmoid resection for diverticulitis leads to a bet-
ter HRQoL compared to conventional resection.
However, as this study aims to reflect the current situa-
tion (in which both conventional and laparoscopic
approaches are used), conventional sigmoid resection
may be used as an alternative.
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